Investigational drug · Phase 2
B244
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acne Vulgaris.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
10
Any phase or sponsor naming "B244"
First trial start
2026
Oct 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "B244", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acne Vulgaris
Approved drugs for the same conditions: Acne · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "B244" as an intervention, largest first.
- B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic DermatitisPivotal-lookingCompleted
AOBiome LLCIndustry
NCT04490109 · 547 participants · Start Jun 24, 2020 · Primary completion Dec 10, 2021
Drug: B244; Vehicle · For: Atopic Dermatitis; Pruritus
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 56 sites in all
- Clinical Trial in Subjects With Mild to Moderate Acne VulgarisPivotal-lookingCompleted
AOBiome LLCIndustry
NCT02832063 · 372 participants · Start Aug 2016 · Primary completion Jul 19, 2017
Drug: B244; Placebo · For: Acne Vulgaris
Sites: Culver City, California
- Study to Determine Safety and Efficacy of B244 in Subjects With Episodic MigrainePivotal-lookingCompleted
AOBiome LLCIndustry
NCT03488563 · 313 participants · Start Mar 30, 2018 · Primary completion Jun 17, 2019
Drug: B244; Vehicle · For: Migraine
Sites: Little Rock, Arkansas; Long Beach, California; Riverside, California · 22 sites in all
- Study to Determine Efficacy, Safety, and Tolerability of B244 as a Topical Spray in Subjects With Moderate to Severe Acne VulgarisPivotal-lookingNot yet recruiting
AOBiome LLCIndustry
NCT07866105 · 176 participants (planned) · Start Oct 2026 · Primary completion Aug 2027
Drug: B244; Vehicle · For: Acne Vulgaris
- A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate RosaceaPivotal-lookingCompleted
AOBiome LLCIndustry
NCT03590366 · 140 participants · Start Jul 2, 2018 · Primary completion Feb 11, 2019
Drug: B244; Vehicle · For: Rosacea
Sites: Clearwater, Florida; Miami, Florida; Miramar, Florida · 9 sites in all
- A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood PressurePivotal-lookingCompleted
AOBiome LLCIndustry
NCT02998840 · 132 participants · Start Nov 2016 · Primary completion Apr 25, 2017
Drug: B244; Vehicle · For: Prehypertension; Hypertension, Stage I
Sites: Birmingham, Alabama; Phoenix, Arizona; Tustin, California · 10 sites in all
- Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic DermatitisPivotal-lookingCompleted
AOBiome LLCIndustry
NCT03235024 · 122 participants · Start Jan 15, 2018 · Primary completion Feb 27, 2019
Drug: B244; Vehicle · For: Atopic Dermatitis Eczema
Sites: Birmingham, Alabama; Phoenix, Arizona; Encino, California · 17 sites in all
AOBiome LLCIndustry
NCT03290248 · 71 participants · Start Sep 19, 2017 · Primary completion Dec 21, 2018
Drug: B244 suspension; Vehicle · For: Allergic Rhinitis; Allergic Rhinitis Due to Grass Pollen; Healthy Volunteers
Sites: Tustin, California; Mississauga, Canada
AOBiome LLCIndustry
NCT02656485 · 36 participants · Start Aug 5, 2015 · Primary completion Mar 1, 2016
Drug: B244; Placebo · For: Acne Vulgaris
Sites: Richardson, Texas
AOBiome LLCIndustry
NCT03775434 · 28 participants · Start Dec 7, 2018 · Primary completion May 18, 2019
Drug: Experimental: B244 · For: Eczema; Atopic Dermatitis
Sites: Bryant, Arkansas; Los Angeles, California; Plainfield, Indiana · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy of Treatments in Reducing Facial Erythema in Rosacea: A Systematic Review.
Hua NJ, Chen J, Geng RSQ, et al. · J Cutan Med Surg 2025
- Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials.
Obed O, Chong AC, Su M, et al. · Expert Opin Emerg Drugs 2024
- Identification of potential inhibitors of Mtb InhA: a pharmacoinformatics approach.
Kamera S, Sharma VK, Prasad V B, et al. · J Biomol Struct Dyn 2024
- Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial.
Silverberg JI, Lio PA, Simpson EL, et al. · EClinicalMedicine 2023
- The interplay between IGF-1R signaling and Hippo-YAP in breast cancer stem cells.
Chan YT, Lin RJ, Wang YH, et al. · Cell Commun Signal 2023
- Modeling surface color discrimination under different lighting environments using image chromatic statistics and convolutional neural networks.
Ponting S, Morimoto T, Smithson HE · J Opt Soc Am A Opt Image Sci Vis 2023
Also in development for Acne Vulgaris
- DenifanstatPhase 31 trial
Sagimet Biosciences Inc. · Acne Vulgaris
- DMT310Phase 31 trial
Dermata Therapeutics · Acne Vulgaris
- HB0043Phase 22 trials
Shanghai Huaota Biopharmaceutical Co., Ltd. · Acne Vulgaris, Hidradenitis Suppurativa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.